Dow Jones 10249.28 -29.47 7:32 am PST, April 15, 2005  NASDAQ 1937.00 -9.71 For info, visit access.smallcapnetwork.com S & P 500 1160.80 -1.25 Change your subscription status here Russell 2000 590.41 -1.53 VOLUME 05: ISSUE 29  Feature: Biocurex - Blood Test Detects More Cancers. MarketNotes. Until a cure for cancer is found, early detection of this disease remains paramount. Biocurex (BOCX.PK) announced today (release below) that it had found that its RECAF blood test detected 92 percent of cervical cancers using only a drop of blood per sample. The current Pap smear test has a detection (sensitivity) rate of between 55-80 percent. Currently, there is no commercial blood test available for the detection of cervical cancer. Today's findings compare favorably with other results Biocurex has previously announced for the early detection of prostate, lung, colorectal and breast cancer. Technically, not much has changed with Biocurex's market action. The shares are trading in a range of $1.25-$1.50 and should they breach $1.60, the next resistance level is $2.60. The shares appear to have had a selling climax a couple of weeks ago that saw the price swiftly move down to $1.05 on heavy volume followed by a decisive bounce. For the uptrend to remain in place, we would like to see the shares maintain a minimum closing level of above $1.20. Our favorable impressions of Biocurex and its technologies continue to grow. The recent Abbott licensing deal, which, in our opinion, doesn't seem to be properly reflected in the share price, merely adds to the potential for both the company's future and influence in the diagnostics community. We suspect that there will be more deals of this caliber in the future as well as significant R&D announcements. For a review of management's discussion of the Abbott deal, have a read of our March 29th and March 31st articles. You say you want a revolution? We believe that Biocurex has the potential to revolutionize the way cancer is detected and ultimately treated. Not to mention the potential savings to the healthcare sector as well as lives saved. The company has further plans to expand its imaging and therapy technologies, which can now be more focused after granting the Abbott semi-exclusive license. Undoubtedly other companies are looking at that deal and given, as the company has stated, the limited number of licenses available, we expect more announcements in the future. As well, the company has retained some core technologies with which it can also move toward commercialization. While Biocurex remains in its formative stage, recent announcements and corporate activities lead us to believe it will soon move to the next threshold as more partners look it over, review and potentially license its exciting technologies. We feel that long-term shareholders should find a spot in the speculative end of their portfolios for this always interesting, never dull company as it grows both its technology and influence in several multi-billion dollar markets.   MARKET NOTES Two things: First, later today. I'll make some comments on the SCBLOG regarding Spectrum's (OTCBB: SPSC) announcement Friday morning re the Horne Engineering deal (http://biz.yahoo.com/bw/050415/155150.html?.v=1 ) as well as some other goings on at the company. The potential and promise for SPSC to become a major player in the industrial and homeland security sector seems to be coming together nicely. Second, over the weekend, we'll bring you a new international idea that will decidedly interest those looking for a growth story in Europe using a service that, while well entrenched in North America, still has significant potential over there. The potential and metrics we feel are compelling. Don't miss it.   Press Release BioCurex's RECAF Blood Test Detects 92 Percent of Cervical Cancers; Current Pap Smear Test Detects Only 55-80 Percent Friday April 15, 10:20 am ET  RICHMOND, British Columbia, April 15, 2005 (PRIMEZONE) -- BioCurex, Inc. (Other OTC:BOCX.PK - News) announced today that it had completed a study in which its RECAF blood test detected 92% of cervical cancers using a drop of blood. The specificity of the test was 95.7%. The study included 25 cervical cancer blood samples and 69 normal blood samples. Currently, there is no commercial blood test available for the detection of cervical cancer. The National Cancer Institute reports a sensitivity of 55-88% for detecting high-grade lesions using a traditional Pap test (http://cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page5). (Certain changes in the diagnostic criteria -- combinations of reference thresholds -- may increase the Pap sensitivity to 70-80% with 95% specificity). The 2005 estimated market size for Pap smears is $1 billion for 2005 (See Note). The diagnosis is performed under the microscope using vaginal material. Dr. Ricardo Moro, BioCurex's CEO stated, ``We are very satisfied with these findings which are in line with our previous results for detecting other types of cancers. The accumulation of positive results strongly suggests that RECAF is expressed by all types of cancer thus lending additional support to the idea of using this cancer marker for routine cancer screening. A RECAF test performed on blood collected for other routine clinical analysis would likely prove much cheaper than the traditional pap test, which currently involves a gynecologist to extract the sample as well as a pathologist (or a sophisticated artificial intelligence system) to read the results. Another very important application for Biocurex's blood test is to improve the follow-up screening of patients who have been operated on for cervical cancer; recurrence of the cancer or its metastases could be detected early by periodically monitoring the blood levels of RECAF, thereby significantly enhancing the chances of patient survival.'' About cervical cancer: Worldwide, cervical cancer claims around 190,000 lives annually, and is the third most common cause of cancer-related deaths. According to the American Cancer Society, the estimated number of women who will be diagnosed with invasive cervical cancer in 2005 is approximately 10,370 in the United States alone. About 3,710 women, the same source states, will die from cervical cancer. About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (BOCX), visit our website at http://www.biocurex.com. Additional Information: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are ``forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. Note: The Worldwide Market for Cancer Diagnostics, Nov. 2002 by Kalorama Information, a division of marketresearch.com. CONTACTS: Fischer Health Media Contact Jennifer Brendel  310-577-7870 Ext. 108 Aurelius Consulting Group Inc. Dave Gentry  800-644-6297 Ext. 104 Chris Bemudaz  800-644-6297 Ext. 103     BioCurex Inc.  604-207-9150 Source: BioCurex, Inc.   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130   Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Under SEC Rule 144, 570,000 shares of the 1 million newly issued restricted shares are now eligible for sale into the public market. TGR Group has submitted the approriate filings to sell the shares.  In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.